Nifty
Sensex
:
:
10829.35
36701.16
88.00 (0.82%)
228.23 (0.63%)

Pharmaceuticals & Drugs

Rating :
43/99  (View)

BSE: 540701 | NSE: DCAL

165.35
-0.80 (-0.48%)
23-Aug-2019 | 3:55PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  167.05
  •  167.50
  •  161.25
  •  166.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  44831
  •  74.13
  •  314.80
  •  160.55

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 2,666.23
  • 13.02
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 3,692.00
  • N/A
  • 0.49

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 61.40%
  • 1.97%
  • 14.23%
  • FII
  • DII
  • Others
  • 0.15%
  • 11.95%
  • 10.30%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 311.48

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 148.40

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 246.64

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Net Sales
521.90
482.24
8.22%
649.72
451.49
43.91%
478.94
459.82
4.16%
447.71
443.84
0.87%
Expenses
402.48
361.48
11.34%
480.33
330.35
45.40%
346.20
338.62
2.24%
319.12
310.85
2.66%
EBITDA
119.42
120.76
-1.11%
169.39
121.14
39.83%
132.74
121.20
9.52%
128.59
132.99
-3.31%
EBIDTM
22.88%
25.04%
26.07%
26.83%
27.72%
26.36%
28.72%
29.96%
Other Income
7.83
6.11
28.15%
19.81
15.50
27.81%
13.37
14.62
-8.55%
14.99
9.01
66.37%
Interest
13.79
14.70
-6.19%
12.65
11.28
12.15%
13.96
12.80
9.06%
15.24
13.37
13.99%
Depreciation
67.26
54.11
24.30%
70.65
50.48
39.96%
57.69
54.96
4.97%
57.50
54.57
5.37%
PBT
46.20
58.06
-20.43%
105.90
74.88
41.43%
74.46
68.06
9.40%
70.84
74.06
-4.35%
Tax
11.89
18.42
-35.45%
30.11
23.74
26.83%
23.09
26.06
-11.40%
26.83
25.67
4.52%
PAT
34.31
39.64
-13.45%
75.79
51.14
48.20%
51.37
42.00
22.31%
44.01
48.39
-9.05%
PATM
6.57%
8.22%
11.66%
11.33%
10.73%
9.13%
9.83%
10.90%
EPS
2.13
2.46
-13.41%
4.70
3.17
48.26%
3.18
2.60
22.31%
2.73
3.00
-9.00%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 18
Mar 17
Net Sales
2,098.27
1,694.78
1,713.69
Net Sales Growth
14.20%
-1.10%
 
Cost Of Goods Sold
423.82
336.93
329.30
Gross Profit
1,674.45
1,357.85
1,384.39
GP Margin
79.80%
80.12%
80.78%
Total Expenditure
1,548.13
1,256.76
1,260.34
Power & Fuel Cost
-
48.67
49.74
% Of Sales
-
2.87%
2.90%
Employee Cost
-
625.40
596.02
% Of Sales
-
36.90%
34.78%
Manufacturing Exp.
-
83.69
98.02
% Of Sales
-
4.94%
5.72%
General & Admin Exp.
-
112.15
81.58
% Of Sales
-
6.62%
4.76%
Selling & Distn. Exp.
-
18.56
58.54
% Of Sales
-
1.10%
3.42%
Miscellaneous Exp.
-
31.36
47.14
% Of Sales
-
1.85%
2.75%
EBITDA
550.14
438.02
453.35
EBITDA Margin
26.22%
25.85%
26.45%
Other Income
56.00
53.02
26.13
Interest
55.64
48.83
49.01
Depreciation
253.10
211.42
213.50
PBT
297.40
230.79
216.97
Tax
91.92
76.22
70.65
Tax Rate
30.91%
33.03%
32.56%
PAT
205.48
154.57
146.32
PAT before Minority Interest
205.48
154.57
146.32
Minority Interest
0.00
0.00
0.00
PAT Margin
9.79%
9.12%
8.54%
PAT Growth
13.42%
5.64%
 
Unadjusted EPS
12.74
9.58
9.01

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 18
Mar 17
Shareholder's Funds
5,107.33
4,813.98
Share Capital
32.28
0.00
Total Reserves
5,075.05
3.98
Non-Current Liabilities
883.96
766.66
Secured Loans
386.16
241.45
Unsecured Loans
138.82
218.67
Long Term Provisions
234.34
221.40
Current Liabilities
1,177.72
993.66
Trade Payables
185.92
85.64
Other Current Liabilities
515.88
457.19
Short Term Borrowings
393.31
384.95
Short Term Provisions
82.61
65.88
Total Liabilities
7,169.01
6,574.30
Net Block
5,060.70
4,847.25
Gross Block
6,621.20
6,187.07
Accumulated Depreciation
1,560.50
1,339.82
Non Current Assets
5,622.87
5,241.25
Capital Work in Progress
150.71
132.88
Non Current Investment
106.60
44.25
Long Term Loans & Adv.
283.31
200.63
Other Non Current Assets
21.55
16.24
Current Assets
1,546.14
1,333.05
Current Investments
94.35
0.00
Inventories
484.56
426.58
Sundry Debtors
444.40
285.55
Cash & Bank
69.06
87.39
Other Current Assets
453.77
172.33
Short Term Loans & Adv.
335.43
361.20
Net Current Assets
368.42
339.39
Total Assets
7,169.01
6,574.30

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 18
Mar 17
Cash From Operating Activity
226.44
302.65
PBT
230.79
216.08
Adjustment
235.49
231.80
Changes in Working Capital
-206.26
-29.43
Cash after chg. in Working capital
260.02
418.45
Interest Paid
0.00
0.00
Tax Paid
-33.58
-115.80
Other Direct Exp. Paid
0.00
0.00
Extra & Other Items
0.00
0.00
Cash From Investing Activity
-297.16
-142.41
Net Fixed Assets
-66.78
Net Investments
-175.91
Others
-54.47
Cash from Financing Activity
77.63
-137.08
Net Cash Inflow / Outflow
6.91
23.16
Opening Cash & Equivalents
58.61
0.00
Closing Cash & Equivalent
65.52
58.61

Financial Ratios

Standalone /

Consolidated
Description
Mar 18
Mar 17
Book Value (Rs.)
316.44
0.00
ROA
2.25%
2.23%
ROE
6.05%
3676.38%
ROCE
4.67%
4.61%
Fixed Asset Turnover
0.26
0.28
Receivable days
78.60
60.82
Inventory Days
98.11
90.86
Payable days
37.47
22.81
Cash Conversion Cycle
139.24
128.86
Total Debt/Equity
0.21
238.62
Interest Cover
5.73
5.43

News Update


  • Dishman Carbogen Amc - Quarterly Results
    13th Aug 2019, 12:57 PM

    Read More
  • Dishman Carbogen Amcis’ arm completes USFDA pre-approval inspection at Switzerland site
    2nd Aug 2019, 11:00 AM

    The inspection was concluded with no Form 483's filed, thus confirming that no critical or major observation was raised during the inspection

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.